相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regional Squamous Cell Carcinomas Following Systemic Sorafenib Therapy and Isolated Limb Infusion for Regionally Advanced Metastatic Melanoma of the Limb
Amanda K. Raymond et al.
ARCHIVES OF DERMATOLOGY (2010)
Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann et al.
CANCER LETTERS (2010)
Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
Zita Dubauskas et al.
CLINICAL GENITOURINARY CANCER (2009)
Eruptive Keratoacanthoma-Type Squamous Cell Carcinomas in Patients Taking Sorafenib for the Treatment of Solid Tumors
Kathleen J. Smith et al.
DERMATOLOGIC SURGERY (2009)
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Jean Philippe Arnault et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The histologic spectrum of epithelial neoplasms induced by sorafenib
Eun Ji Kwon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Array of cutaneous adverse effects associated with sorafenib
Heidi H. Kong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma?
Joshua C. Mandrell et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2009)
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
David S. Hong et al.
ARCHIVES OF DERMATOLOGY (2008)
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
Julien Autier et al.
ARCHIVES OF DERMATOLOGY (2008)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Diagnosis and follow-up of keratoacanthoma-like lesions: Clinical-histologic study of 43 cases
Renata Ferreira Magalhaes et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2008)
CUTANEOUS SQUAMOUS CELL CARCINOMA AND HUMAN PAPILLOMAVIRUS
R. Corbalan-Velez et al.
ACTAS DERMO-SIFILIOGRAFICAS (2007)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Keratoacanthomas associated with sorafenib therapy
Heidi H. Kong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
M. E. Lacouture et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2006)
Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization
Ole Petter F. Clausen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals
KJ Purdie et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin
CA Harwood et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers
TC Putti et al.
MODERN PATHOLOGY (2004)
Keratoacanthoma: A clinico-pathologic enigma
RA Schwartz
DERMATOLOGIC SURGERY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals
C Masini et al.
ARCHIVES OF DERMATOLOGY (2003)
Human papillomaviruses and non-melanoma skin cancer
CA Harwood et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2002)
The risk of progression to invasive disease
RG Glogau
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2000)
分享论文
